60
Participants
Start Date
March 4, 2014
Primary Completion Date
September 1, 2014
Study Completion Date
March 4, 2015
Levonorgestrel
Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
Nevirapine
Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
Efavirenz
Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
Infectious Diseases Institute, Kampala
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Makerere University
OTHER
University of Liverpool
OTHER
University of Nebraska
OTHER